Hepatocyte growth factor HGF/c-Met signalling has been reported to affect vascular calcification, an end point of endothelial dysfunction in the atherosclerotic spectrum.17 Heparan sulfate acts as a ligand for activation of the HGF/c-Met signalling pathway, thus one can attenuate this pathway using small molecule heparan sulfate-glycomimetics and reduce vascular calcification as a risk factor for cardiovascular diseases. Here, MET is linked to endothelial dysfunction.